drugset / Trial / NCT00608894

LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis

NCT00608894

Phase 2 Terminated 13 enrolled Veloxis Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

An open-label, multi-center, prospective, randomized study to evaluate the efficacy, safety and tolerability of LCP-Tacro tablets given once daily vs. azathioprine, each in combination with prednisone, for the treatment of autoimmune hepatitis (AIH).

Timeline

Start
2007-12
Primary completion
2009-04
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Azathioprine Small molecule 50 mg
Comparator Azathioprine Small molecule 100 mg
Subject Tacrolimus Small molecule 1 mg
Subject Tacrolimus Small molecule 2 mg

Indications